| iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients |
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival |
globenewswire.com |
2025-05-13 11:55:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? |
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-02 15:00:57 |
Czytaj oryginał (ang.) |
| iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates |
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. |
globenewswire.com |
2025-04-28 20:30:00 |
Czytaj oryginał (ang.) |
| iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 |
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois. |
globenewswire.com |
2025-03-25 18:35:00 |
Czytaj oryginał (ang.) |
| iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial - EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25 - Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 |
globenewswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless |
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability. |
seekingalpha.com |
2025-02-27 13:00:16 |
Czytaj oryginał (ang.) |
| All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy |
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-13 15:01:14 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 |
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications. |
seekingalpha.com |
2024-12-17 21:01:58 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress |
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized to focus resources on other programs |
globenewswire.com |
2024-12-12 10:55:00 |
Czytaj oryginał (ang.) |
| iTeos to Participate in Upcoming Investor Conferences |
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates |
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones |
globenewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths |
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid. |
investors.com |
2024-09-16 17:05:24 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session |
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. |
benzinga.com |
2024-09-16 12:44:05 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT |
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval. |
seekingalpha.com |
2024-09-15 07:37:27 |
Czytaj oryginał (ang.) |
| iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients |
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET |
globenewswire.com |
2024-09-14 06:30:00 |
Czytaj oryginał (ang.) |
| iTeos to Participate in Upcoming Investor Conferences |
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September: |
globenewswire.com |
2024-08-28 20:30:00 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 |
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain. |
globenewswire.com |
2024-08-20 12:30:00 |
Czytaj oryginał (ang.) |
| ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates |
ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago. |
zacks.com |
2024-08-08 13:21:23 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer |
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. |
globenewswire.com |
2024-08-05 11:00:00 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism |
iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts. Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations. |
seekingalpha.com |
2024-07-09 01:00:00 |
Czytaj oryginał (ang.) |
| iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK |
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with first-line advanced, unresectable, or metastatic PD-L1 high NSCLC. This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug. |
globenewswire.com |
2024-07-08 11:00:00 |
Czytaj oryginał (ang.) |
| iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer |
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer (NSCLC). |
globenewswire.com |
2024-06-17 13:00:00 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics to raise $120 million via registered direct offering |
iTeos Therapeutics Inc (NASDAQ: ITOS) is up 30% today after announcing plans of a registered direct offering. iTeos Therapeutics stock pops on Q1 earnings The biotechnology company will sell a total of 1,142,857 shares at $17.50 each which translates to a 44% premium on its previous close. |
invezz.com |
2024-05-10 13:45:14 |
Czytaj oryginał (ang.) |
| iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates |
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy - GSK to provide update on GALAXIES program at upcoming investor event in June - RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close - Pro forma cash and investment balance of $715 million as of March 31, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones |
globenewswire.com |
2024-05-10 12:26:00 |
Czytaj oryginał (ang.) |
| iTeos Therapeutics Announces $120 Million Registered Direct Offering |
- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through 2027 |
globenewswire.com |
2024-05-10 12:24:00 |
Czytaj oryginał (ang.) |
| iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 |
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1) in oncology, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California. |
globenewswire.com |
2024-04-07 20:30:00 |
Czytaj oryginał (ang.) |
| iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors |
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. |
globenewswire.com |
2024-03-06 09:01:00 |
Czytaj oryginał (ang.) |